Brief: Lumos Diagnostics Seeks Trading Halt Pending Update On FDA Response
24/03/2026 22:22
March 25 (Reuters) - Lumos Diagnostics Holdings Ltd LDX.AX: SEEKS TRADING HALT PENDING UPDATE ON FDA RESPONSE TO FEBRIDX CLIA WAIVER APPLICATION Further company coverage: LDX.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lumos Diagnostics Holdings
See all newsBrief: Lumos Diagnostics Posts FY26 Revenue Of $13.2 Million
Australia's Lumos Diagnostics soars on bagging purchase order for diagnostic test
Brief: Lumos Diagnostics Receives $767,800 Febridx Order From Phase Scientific
Brief: Lumos Diagnostics Signs Exclusive Distribution Agreement For Febridx In Romania
Brief: Lumos Diagnostics Posts FY26 Revenue Rises 6% To $13.2 Million